Information Provided By: 
Fly News Breaks for November 7, 2018
ONCE
Nov 7, 2018 | 07:57 EDT
As previously reported, Raymond James upgraded Spark Therapeutics to Strong Buy from Outperform and reduced its price target to $72 from $82. Analyst Reni Benjamin said shares are trading at a 12-month low at a time when his confidence in the Hem A program has increased, and the clinical pipeline is expanding and will soon include Pompe disease as well as a novel asset to tackle Hem A patients with Factor VIII inhibitors.
News For ONCE From the Last 2 Days
There are no results for your query ONCE
